Skip to Main Content
Contribute Try STAT+ Today

Last June, Amgen excited cancer scientists and investors alike with the first tumor-shrinking results from a medicine targeted against the “undruggable” KRAS protein.

On Sunday, the biotech presented another round of data on the KRAS-blocking drug called AMG 510. Like this past summer, tumor responses hover around 50% — more impressive now because the analysis comprises a larger number of lung cancer patients. But the details also reveal some questions about AMG 510 that will require further time and study to answer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.